Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Liguria – page 56

810 clinical trials in Liguria, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Liguria at a glance
810
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

810 trials in Liguria

Open in trial search

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Utreloxastat
  • Sponsor:PTC Therapeutics Inc.

Acromegaly

Not recruiting

Study of long-term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Octreotide Hydrochloride
  • Sponsor:Camurus AB

Neuroblastoma+4

Not recruiting

Study on Ribociclib, Topotecan, and Temozolomide for Children and Young Adults (12 months - 21 years) with Relapsed or Refractory Neuroblastoma and Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ribociclib
  • Sponsor:Novartis Pharma AG

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Study on the Effects of Fidrisertib for Treating Fibrodysplasia Ossificans Progressiva in Children and Adults

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Fidrisertib
  • Sponsor:Clementia Pharmaceuticals Inc. An Ipsen Company

Asthmatic crisis

Not recruiting

Study on the Effects of Verekitug (UPB-101) for Adults with Severe Asthma

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 kappa monoclonal antibody against CRLF2
  • Sponsor:Upstream Bio Inc.

Cystic fibrosis

Not recruiting

Study on the Effects of Dirocaftor, Posenacaftor, and Nesolicaftor for Adults with Cystic Fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dirocaftor
  • Sponsor:Universitair Medisch Centrum Utrecht

Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:IO102 hydrochloride
  • Sponsor:Io Biotech ApS

Study Comparing Human Normal Immunoglobulin and Placebo for Children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Takeda Development Center Americas Inc.

Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:Novartis Pharma AG

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Liguria

What the registry says about research in the country

01 HIV Treatment Research

Clinical research focusing on early treatment switching strategies for HIV-1 infected individuals who have achieved viral suppression. The trials examine the effectiveness of transitioning from three-drug to two-drug antiretroviral therapy.

  • Viral Suppression Maintenance
  • Treatment Simplification
  • Long-term Safety Assessment

The study aims to evaluate a novel approach using dolutegravir/lamivudine combination therapy, potentially offering patients a more streamlined treatment regimen while maintaining therapeutic effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.